Last updated: 11/03/2018 09:34:52
A study to evaluate the immune response and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine/Cervarix TM vaccine in healthy females aged 15-25 years
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly in healthy female subjects aged 15 – 25 years
Trial description: Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women. This study will evaluate the immunogenicity and safety of the GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) vaccine.The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Number of subjects seroconverted for anti-human papilloma virus 16 (Anti-HPV-16) and anti-human papilloma virus 18 (Anti-HPV-18) antibodies
Timeframe: One month post Dose 3 (Month 7)
Secondary outcomes:
Anti-HPV-16 and anti-HPV-18 antibody titres
Timeframe: Before vaccination (PRE) and one month post Dose 3 (Month 7)
Number of subjects reporting solicited local symptoms
Timeframe: During the 7-day (Days 0-6) period following each vaccination
Number of subjects reporting solicited general symptoms
Timeframe: During the 7-day (Days 0-6) period following each vaccination
Number of subjects reporting unsolicited adverse events (AE)
Timeframe: During the 30-day (Days 0-29) period following each vaccination
Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions
Timeframe: From Day 0 up to Month 7
Number of subjects reporting serious adverse events (SAE)
Timeframe: From Day 0 up to Month 7
Number of subjects with pregnancies and their outcome
Timeframe: from Day 0 up to Month 7
Interventions:
Biological/vaccine: HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
Biological/vaccine: Placebo
Enrollment:
225
Observational study model:
Not applicable
Primary completion date:
2008-30-03
Time perspective:
Not applicable
Clinical publications:
Kim CS et al. (2011) Human Papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and Safety in 15–25 year old healthy Korean women. J Gynecol Oncol. 22(2):67-75.
Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638.
Medical condition
Infections, Papillomavirus
Product
SB580299
Collaborators
Not applicable
Study date(s)
June 2007 to March 2008
Type
Interventional
Phase
3
Participation criteria
Sex
Female
Age
15 - 25 years
Accepts healthy volunteers
Yes
- Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- A female between, and including, 15 and 25 years of age at the time of the first vaccination.
- Use of any investigational or non-registered product (drug or vaccine) other than the study/ control vaccine within 30 days preceding the first dose of study/ control vaccine, or planned use during the study period.
- Pregnant or breastfeeding.
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- A female between, and including, 15 and 25 years of age at the time of the first vaccination.
- Written informed assent obtained from the subject and informed consent obtained from the parent or guardian of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Subjects must have a negative urine pregnancy test.
- Subjects of childbearing potential at the time of study entry must be abstinent, or must be using adequate contraceptive precautions for 30 days prior to vaccination and must agree to continue such precautions for two months after completion of the vaccination series.
Exclusion criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study/ control vaccine within 30 days preceding the first dose of study/ control vaccine, or planned use during the study period.
- Pregnant or breastfeeding.
- Planning to become pregnant or likely to become pregnant.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. However, the administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
- Previous administration of components of the investigational vaccine
- Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
- Any medically diagnosed or suspected immunodeficient condition such as HIV infection based on medical history and physical examination.
- History of thrombocytopenia or hemostatic disorder in which case the study vaccine should under no circumstances be administered intramuscularly.
- History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study/control vaccines.
- Hypersensitivity to latex.
- Known acute or chronic, clinically significant neurologic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.
- History of chronic condition(s) requiring treatment.
- Administration of immunoglobulins and/or any blood product within three months preceding the first dose of study/control vaccine or planned administration during the study period. Enrolment will be deferred until the subject is outside of specified window.
- Acute disease at the time of enrolment.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2008-30-03
Actual study completion date
2008-30-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website